Acadia Pharmaceuticals Announces Top-Line Results from Phase 3 ADVANCE-2 Trial of Pimavanserin in Negative Symptoms of Schizophrenia

Acadia Pharmaceuticals Inc. today announced top-line results from the Phase 3 ADVANCE-2 trial evaluating pimavanserin for the treatment of negative symptoms of schizophrenia. Pimavanserin did not demonstrate a statistically significant improvement...

Related Keywords

Steve Davis ,Acadia Pharmaceuticals Inc ,Linkedin ,Exchange Commission ,Acadia Pharmaceuticals Announces Top ,Acadia Pharmaceuticals ,Twitter ,Exchange Commission On ,Nasdaq ,Pharmaceuticals Announces Top Line Results ,Negative Symptoms ,Negative Symptom ,Chief Executive ,Private Securities Litigation Reform Act ,